Effect of Perineural Dextrose Injection on Myofascial Pain Syndrome

S. Khalil
{"title":"Effect of Perineural Dextrose Injection on Myofascial Pain Syndrome","authors":"S. Khalil","doi":"10.33091/amj.2022.176307","DOIUrl":null,"url":null,"abstract":"Background: Myofascial pain syndrome (MFPS) is defined as the motor, sensory, and autonomic signs resulting from trigger points (TrPs). Objectives: To assess the effectiveness of the perineural injection in patients with MFPS. Materials and methods: The study was conducted at AL Ramadi Teaching Hospital, Department of Rheumatology, Ramadi City, Iraq. The study period was from June 2019 to January 2021. A retrospective review of 100 patients with prospectively collected clinical and radiologic data was performed to evaluate the effectiveness of perineural injection on MFPS. A 3 ml of 5% dextrose solution was managed sub-cutaneous straight at the labeled chronic constrictive injury and tender spots rounding the knee. The VAS and WOMAC were calculated for each participant at the time of the presentation and 1, 3, and 6 months following treatment. Results: The mean age of the patients was 60.93 ± 6.17 years (25-70 years). Three-quarters (75/100) of the cases were female. Seventy subjects were from the age group ≥ 40 years, while the remaining 30 cases were from the age group < 40 years. Fifty-five cases were with right-sided involvement. Successful results were achieved in 90% of the participants. There were no statistically significant differences between the effective and not effective groups regarding the age, gender, and the involved side (P-value > 0.05). There was a reduction in the mean VAS (8.47 ± 0.77) of pain and WOMAC (78.99 ± 5.69) score at the time of presentation to 1.87 ± 1.32 for the VAS and 17.84 ± 4.66 WOMAC at 6-months post-injection period. No complications were reported in all patients apart from mild pain at the injection site. Conclusion: Perineural dextrose injection was successful in 90% of the patients with MFPS. This modality results in a sharp reduction of both VAS and WOMAC scores from the time of the presentation to 6-months post-treatment. We recommend using this modality because it is easy, effective, and safe.","PeriodicalId":378741,"journal":{"name":"Al- Anbar Medical Journal","volume":"40 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Al- Anbar Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33091/amj.2022.176307","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Myofascial pain syndrome (MFPS) is defined as the motor, sensory, and autonomic signs resulting from trigger points (TrPs). Objectives: To assess the effectiveness of the perineural injection in patients with MFPS. Materials and methods: The study was conducted at AL Ramadi Teaching Hospital, Department of Rheumatology, Ramadi City, Iraq. The study period was from June 2019 to January 2021. A retrospective review of 100 patients with prospectively collected clinical and radiologic data was performed to evaluate the effectiveness of perineural injection on MFPS. A 3 ml of 5% dextrose solution was managed sub-cutaneous straight at the labeled chronic constrictive injury and tender spots rounding the knee. The VAS and WOMAC were calculated for each participant at the time of the presentation and 1, 3, and 6 months following treatment. Results: The mean age of the patients was 60.93 ± 6.17 years (25-70 years). Three-quarters (75/100) of the cases were female. Seventy subjects were from the age group ≥ 40 years, while the remaining 30 cases were from the age group < 40 years. Fifty-five cases were with right-sided involvement. Successful results were achieved in 90% of the participants. There were no statistically significant differences between the effective and not effective groups regarding the age, gender, and the involved side (P-value > 0.05). There was a reduction in the mean VAS (8.47 ± 0.77) of pain and WOMAC (78.99 ± 5.69) score at the time of presentation to 1.87 ± 1.32 for the VAS and 17.84 ± 4.66 WOMAC at 6-months post-injection period. No complications were reported in all patients apart from mild pain at the injection site. Conclusion: Perineural dextrose injection was successful in 90% of the patients with MFPS. This modality results in a sharp reduction of both VAS and WOMAC scores from the time of the presentation to 6-months post-treatment. We recommend using this modality because it is easy, effective, and safe.
神经周围葡萄糖注射对肌筋膜疼痛综合征的影响
背景:肌筋膜疼痛综合征(MFPS)被定义为由触发点(TrPs)引起的运动、感觉和自主神经体征。目的:评价神经周注射治疗MFPS的疗效。材料和方法:本研究在伊拉克拉马迪市AL拉马迪教学医院风湿科进行。研究时间为2019年6月至2021年1月。回顾性分析100例患者的临床和影像学资料,以评估神经周围注射治疗MFPS的有效性。在标记的慢性收缩性损伤和膝盖周围的压痛点处直接皮下注射3ml 5%葡萄糖溶液。计算每个参与者在就诊时以及治疗后1、3和6个月的VAS和WOMAC。结果:患者平均年龄为60.93±6.17岁(25 ~ 70岁)。四分之三(75/100)的病例为女性。≥40岁年龄组70例,< 40岁年龄组30例。右侧受累55例。90%的参与者取得了成功的结果。有效组与无效组在年龄、性别、受累方等方面差异均无统计学意义(p值> 0.05)。注射后6个月,疼痛和WOMAC的VAS(8.47±0.77)分和WOMAC(78.99±5.69)分分别降至1.87±1.32分和17.84±4.66分。除注射部位轻微疼痛外,所有患者均无并发症。结论:90%的MFPS患者神经周葡萄糖注射成功。这种方式导致VAS和WOMAC评分从出现时到治疗后6个月的急剧下降。我们推荐使用这种方式,因为它简单、有效和安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信